131 related articles for article (PubMed ID: 37824214)
1. Innovative UV Protocols Based on Straightforward Mathematical Filtration for Concurrent Estimation of Two Antidiabetic Drugs in Their Brand-New Combination: A Comparative Study.
Nour IM; Mohamed AR; Badrawy M
J AOAC Int; 2024 Jan; 107(1):40-45. PubMed ID: 37824214
[TBL] [Abstract][Full Text] [Related]
2. Mean centering-triple divisor and ratio derivative-zero crossing for simultaneous determination of some diabetes drugs in their quaternary mixture with severely overlapping spectra.
M Amin KF; Abdullah AM; Fakhre NA
Spectrochim Acta A Mol Biomol Spectrosc; 2019 Nov; 222():117261. PubMed ID: 31228859
[TBL] [Abstract][Full Text] [Related]
3. Flourimetric study on antidiabetic combined drugs; empagliflozin and linagliptin in their pharmaceutical formulation and human plasma.
Elmasry MS; Hasan MA; Hassan WS; Merey HA; Nour IM
Spectrochim Acta A Mol Biomol Spectrosc; 2021 Mar; 248():119258. PubMed ID: 33310272
[TBL] [Abstract][Full Text] [Related]
4. Simple mathematical data processing method for the determination of sever overlapped spectra of linagliptin and empagliflozin in their pure forms and pharmaceutical formulation: Fourier self deconvulated method.
Elmasry MS; Hassan WS; Merey HA; Nour IM
Spectrochim Acta A Mol Biomol Spectrosc; 2021 Jun; 254():119609. PubMed ID: 33684852
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of simple spectrophotometric and chemometric methods for simultaneous determination of empagliflozin and metformin: Applied to recently approved pharmaceutical formulation.
Ayoub BM
Spectrochim Acta A Mol Biomol Spectrosc; 2016 Nov; 168():118-122. PubMed ID: 27288963
[TBL] [Abstract][Full Text] [Related]
6. Determination of linagliptin and empagliflozin by UPLC and HPTLC techniques aided by lean six sigma approach.
El-Desouky EA; Abdel-Raoof AM; Abdel-Fattah A; Abdel-Zaher A; Osman AOE; Abdel-Monem AH; Morshedy S
Biomed Chromatogr; 2021 Jul; 35(7):e5102. PubMed ID: 33629452
[TBL] [Abstract][Full Text] [Related]
7. Different resolution techniques for management of overlapped spectra: Application for the determination of novel co-formulated hypoglycemic drugs in their combined pharmaceutical dosage form.
Moussa BA; Mahrouse MA; Fawzy MG
Spectrochim Acta A Mol Biomol Spectrosc; 2018 Dec; 205():235-242. PubMed ID: 30025293
[TBL] [Abstract][Full Text] [Related]
8. Stability-indicating ultra performance liquid chromatography method development and validation for simultaneous estimation of metformin, linagliptin, and empagliflozin in bulk and pharmaceutical dosage form.
Vankalapati KR; Alegete P; Boodida S
Biomed Chromatogr; 2021 Apr; 35(4):e5019. PubMed ID: 33146442
[TBL] [Abstract][Full Text] [Related]
9. Comparative Study Between Multivariate and Univariate Analysis of Two Antidiabetic Combinations.
Abdel-Ghany MF; Abdel-Aziz O; Ayad MF; Tadros MM
J AOAC Int; 2017 Sep; 100(5):1379-1391. PubMed ID: 28421983
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous estimation of two anti-diabetic drugs; Linagliptin and empagliflozin in their tablet by chemometric spectrophotometry.
Kamal AH; Hammad SF; Salim MM; Elkhodary MM; Marie AA
Spectrochim Acta A Mol Biomol Spectrosc; 2024 Jan; 305():123556. PubMed ID: 37866257
[TBL] [Abstract][Full Text] [Related]
11. Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes.
Tan X; Hu J
Ann Endocrinol (Paris); 2016 Oct; 77(5):557-562. PubMed ID: 27062036
[TBL] [Abstract][Full Text] [Related]
12. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin.
Aronson R
Curr Med Res Opin; 2015 May; 31(5):901-11. PubMed ID: 25775379
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes.
Rizos CV; Filippatos TD; Elisaf MS
Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):117-125. PubMed ID: 29241374
[TBL] [Abstract][Full Text] [Related]
14. Empagliflozin/Linagliptin: A Review in Type 2 Diabetes.
Kim ES; Deeks ED
Drugs; 2015 Sep; 75(13):1547-57. PubMed ID: 26323340
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous spectrophotometric determination of compounds having relatively disparate absorbance and concentration ranges; application to antidiabetic formulation of linagliptin and metformin.
Abdalla OM; Abdel-Megied AM; Saad AS; Soliman SS
Spectrochim Acta A Mol Biomol Spectrosc; 2018 Oct; 203():112-117. PubMed ID: 29860167
[TBL] [Abstract][Full Text] [Related]
16. Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes.
Lingvay I; Beetz N; Sennewald R; Schuler-Metz A; Bertulis J; Loley C; Lang B; Lippert C; Lee J; Manning LS; Terada D
Postgrad Med; 2020 May; 132(4):337-345. PubMed ID: 32366156
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials.
Watada H; Yamauchi T; Yamamoto F; Taniguchi A; Yarush L; Heilmann C; Yasui A
Expert Opin Drug Saf; 2020 Sep; 19(9):1193-1202. PubMed ID: 32552153
[TBL] [Abstract][Full Text] [Related]
18. Architecting novel multilayer nanosponges for co-administration of two drugs managing high-risk type II diabetes mellitus patients suffering from cardiovascular diseases.
Hammad RW; Sanad RA; Abdelmalak NS; Latif R
Int J Biol Macromol; 2022 Nov; 220():1429-1443. PubMed ID: 36115452
[TBL] [Abstract][Full Text] [Related]
19. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA
Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin/linagliptin single-tablet combination: first-in-class treatment option.
Woo V
Int J Clin Pract; 2015 Dec; 69(12):1427-37. PubMed ID: 26303997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
